Attributable causes of cancer in China

Wang, J.B.; Jiang, Yong; Liang, Hao; Li, P.; Xiao, Huijuan; Ji, Jun; Wang, Xiang; Shi, Jufang; Fan, Yongli; Li, L.; Wang, D.; Deng, Shengfu; Chen, W.Q.; Wei, Wenqiang; Qiao, You‐Lin; Boffetta, Paolo

doi:10.1093/annonc/mds139

Cited by 95 publications

(89 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Air pollution is recognized as an important etiological factor in cancer and other diseases [13–18]. The predominant human-associated causes of air pollution in China include transportation, power generation, industry, biomass burning, and domestic heating and cooking [19].…”

Section: Environmental Pollutionmentioning

confidence: 99%

Cancer prevention and control: alarming challenges in China

Bode

Dong

Wang

2016

National Science Review

View full text Add to dashboard Cite

China is geographically the third largest country in the world and the most populated low-to-middle-income country. Cancer incidence and mortality rates for some cancers in the USA and European countries have steadily decreased over the last decades, whereas the incidence and mortality of certain cancers in China have been increasing at an alarming speed. Rapid industrialization and urbanization in China have been accompanied by incredible changes in lifestyle and environment combined with an aging population. Mortality caused by lung, colorectal and breast cancers has been steadily increasing, whereas cancer mortality from gastric, esophageal and cervical tumors has tended to decrease. Similar to what has occurred in the United States, unhealthy lifestyles in China, including heavy smoking and poor diet combined with pollution, have contributed to increased cancer risk. China is facing many challenges in cancer treatment and prevention for the general population. The major areas that need to be addressed in the control of cancer in China include cancers associated with environmental pollution, tobacco use, occupational carcinogens, infection, excessive alcohol consumption, dietary deficiencies and obesity. In this perspective, we review the problems in each area and suggest ideas for future directions in cancer research and strategies and actions to reduce the incidence of cancer in China.

show abstract

Section: Environmental Pollutionmentioning

confidence: 99%

Cancer prevention and control: alarming challenges in China

Bode

Dong

Wang

2016

National Science Review

View full text Add to dashboard Cite

show abstract

“…In China, there has been a drastic increase in lung cancer-associated mortality since 1970 (2). At present, treatments for NSCLC are marginally effective (3) and the primary target for treatment of NSCLCs is the epidermal growth factor receptor (EGFR) pathway (4).…”

Section: Introductionmentioning

confidence: 99%

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations

Zang

Yang

Zhao

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The T790M mutational basis of treatment failure, following treatment via alteration of the epidermal growth factor receptor (EGFR) pathway, is a well-known anomaly in patients with non-small cell lung cancer (NSCLC). The T790M mutation activates the kinase domain, causing tyrosine kinase inhibitors, such as gefitinib, to elicit little or no response. To overcome this acquired resistance in NSCLC cells, the present study utilized a structure-based drug designing method to identify a novel lead compound. An in-house traditional Chinese medicinal compound database was used and following initial virtual screening, pre-absorption, distribution, metabolism and excretion/Tox and automated docking analyses, nardosinon was selected as the most appropriate candidate for further analysis. Two NSCLC cell lines, PC9GR4 and H2347, were used to test nardosinon and the results were compared with gefitinib. Results from an initial cell death assay revealed that nardosinon was able to induce cell death in NSCLC cells with and without the T790M mutation. These findings suggest that nardosinon may be an effective pharmacological compound for NSCLC treatment, including T790M EGFR mutant NSCLC cells.

show abstract

“…Thus, risk factors for development of EC and patients at risk have not been well understood yet. Up to now, cigarette smoking, alcohol consumption, low vegetable intake, and family history of cancer have been identified as risk factors for this disease [3,4]. However, all these known factors account for a small number of EC cases.…”

Section: Introductionmentioning

confidence: 99%